经鼻持续气道正压与经鼻间歇正压通气及无创高频振荡通气在极早产或更严重呼吸衰竭新生儿拔管后支持中的效果:一项随机临床试验的二次分析
该研究为NASONE多中心随机临床试验的预设二次分析,纳入中国三级学术NICU中2017年12月至2021年5月 enrolled 的1137名早产儿中的3个预设亚组:胎龄≤28周+6天(455例)、出生后有创通气>1周(375例)、拔管前或拔管后24小时内CO2>50 mm Hg(307例)。干预为首次拔管后至NICU出院期间使用NCPAP、NIPPV或NHFOV,NHFOV气道压力高于NIPPV和NCPAP。共同主要结局为NICU住院期间总有创机械通气时间、再插管需求和按原试验方案计算的无呼吸机天数。结果显示NIPPV和NHFOV较NCPAP显著减少再插管(风险差范围-28%至-15%,NNT 3-7)和早期再插管(风险差范围-24%至-20%),有创通气时间更短(均差范围-5.0天至-2.3天),NHFOV组中重度支气管肺发育不良更少(范围-12%至-10%,NNT 8-9),NIPPV与NHFOV之间共同主要结局无差异。
要点
- 极早产(≤28周+6天)或病情较重亚组中,NIPPV和NHFOV较NCPAP显著减少再插管,风险差范围-28%至-15%,NNT 3-7名婴儿。
- NIPPV和NHFOV较NCPAP显著减少早期再插管,风险差范围-24%至-20%,且因难治性低氧血症导致的再插管更少。
- NIPPV和NHFOV组有创机械通气时间较NCPAP组更短,均差范围-5.0天至-2.3天。
- NHFOV组中重度支气管肺发育不良较NCPAP组显著减少,范围-12%至-10%,NNT 8-9名婴儿,且各亚组拔管后气体交换更好。
- NIPPV与NHFOV之间共同主要结局无差异,无显著交互效应;三种干预在不同平均气道压下安全性相当。
适用人群与场景
- 中国三级学术NICU中纳入NASONE试验的早产儿,属于3个预设亚组:胎龄≤28周+6天、出生后有创机械通气>1周、拔管前或拔管后24小时内CO2>50 mm Hg。
- 研究场景为NICU,干预从首次拔管后持续至NICU出院。
诊断标准与关键阈值
- 亚组1:胎龄≤28周+6天。
- 亚组2:出生后有创机械通气>1周。
- 亚组3:拔管前或拔管后24小时内CO2>50 mm Hg。
处置流程与药物剂量
- 首次拔管后至NICU出院期间分别给予NCPAP、NIPPV或NHFOV,NHFOV气道压力高于NIPPV,NIPPV气道压力高于NCPAP。
研究设计与关键结果
- 研究类型:多中心随机临床试验的预设二次分析,纳入1137名早产儿中的3个预设亚组:胎龄≤28周+6天455例(男279例,61.3%)、有创通气>1周375例(男218例,58.1%)、CO2>50 mm Hg 307例(男183例,59.6%)。
- NIPPV和NHFOV较NCPAP显著减少再插管,风险差范围-28%(95%CI -39%至-17%)至-15%(95%CI -25%至-4%),NNT 3-7名婴儿。
- NIPPV和NHFOV较NCPAP显著减少早期再插管,风险差范围-24%(95%CI -35%至-14%)至-20%(95%CI -30%至-10%),且因难治性低氧血症导致的再插管更少。
- NIPPV和NHFOV组有创机械通气时间较NCPAP组更短,均差范围-5.0天(95%CI -6.8至-3.1天)至-2.3天(95%CI -4.1至-0.4天)。
- NIPPV与NHFOV之间共同主要结局无差异,无显著交互效应。
- NHFOV组中重度支气管肺发育不良较NCPAP组显著减少,范围-12%至-10%,NNT 8-9名婴儿,且各亚组拔管后气体交换更好。
- 三种干预在不同平均气道压下安全性相当。
证据类型、等级与局限
- 证据类型:多中心随机临床试验的预设二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在极早产(≤28周+6天)或病情较重(有创通气>1周、拔管前或拔管后24小时内CO2>50 mm Hg)的早产儿中,拔管后使用NIPPV或NHFOV较NCPAP可减少再插管和早期再插管、缩短有创通气时间,NIPPV与NHFOV效果相当。
指南或共识出处
- NASONE试验(ClinicalTrials.gov Identifier: NCT03181958)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The NASONE (Nasal Oscillation Post-Extubation) trial showed that noninvasive high-frequency oscillatory ventilation (NHFOV) slightly reduces the duration of invasive mechanical ventilation (IMV) in preterm infants, whereas NHFOV and noninvasive intermittent positive pressure ventilation (NIPPV) result in fewer reintubations than nasal continuous positive airway pressure (NCPAP). It is unknown whether NHFOV is similarly effective in extremely preterm neonates or in those with more severe respiratory failure (based on the duration of previous ventilation and CO2 levels).
OBJECTIVE: To clarify whether NHFOV is better than NIPPV and NCPAP in reducing the duration of IMV in extremely preterm neonates or those with severe respiratory failure.
DESIGN, SETTING, AND PARTICIPANTS: This study is a predefined secondary analyses of a multicenter randomized clinical trial that was performed at tertiary academic neonatal intensive care units (NICUs) in China. Participants included neonates enrolled in the NASONE trial between December 2017 and May 2021 and belonging to 3 predefined subgroups: (1) born at less than or equal to 28 weeks' (plus 6 days) gestation, (2) invasively ventilated for more than 1 week from birth, and (3) with CO2 greater than 50 mm Hg before or in the 24 hours after extubation. Data analysis was performed in August 2022.
INTERVENTION: NCPAP, NIPPV, or NHFOV since the first extubation and until NICU discharge, with airway pressure higher in NHFOV than in NIPPV and than in NCPAP.
MAIN OUTCOMES AND MEASURES: The co-primary outcomes were total duration of IMV during the NICU stay, need for reintubation, and ventilator-free days calculated as per the original trial protocol. Outcomes were analyzed on an intention-to-treat basis as for the whole trial, and subgroup analyses followed the original statistical plan.
RESULTS: Among 1137 preterm infants, 455 (279 boys [61.3%]) were born at 28 weeks' gestation or less, 375 (218 boys [58.1%]) underwent IMV for more than 1 week from birth, and 307 (183 boys [59.6%]) had CO2 greater than 50 mm Hg before or in the 24 hours after extubation. Both NIPPV and NHFOV were associated with significantly fewer reintubations (risk difference range, -28% [95% CI, -39% to -17%] to -15% [95% CI, -25% to -4%]; number needed to treat, 3-7 infants) and early reintubations (risk difference range, -24% [95% CI, -35% to -14%] to -20% [95% CI, -30% to -10%]) than NCPAP, and these reintubations were less frequently due to refractory hypoxemia. IMV was shorter in the NIPPV and NHFOV groups (mean difference range, -5.0 days [95% CI, -6.8 to -3.1 days] to -2.3 days [95% CI, -4.1 to -0.4 days]) than in the NCPAP group. Co-primary outcomes were not different between NIPPV and NHFOV; there was no significant interaction effect. Infants in the NHFOV group showed significantly less moderate-to-severe bronchopulmonary dysplasia than infants in the NCPAP group (range, -12% to -10%; number needed to treat, 8-9 infants) and better postextubation gas exchange in all subgroups. The 3 interventions were provided at different mean airway pressure and were equally safe.
CONCLUSIONS AND RELEVANCE: The subgroup analyses of extremely preterm or more ill infants confirm the results obtained in the whole population: NIPPV and NHFOV appeared equally effective in reducing duration of IMV compared with NCPAP.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03181958.
参考来源
- Zhu X, Li F, Shi Y, et al. Effectiveness of Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation vs Noninvasive High-Frequency Oscillatory Ventilation as Support After Extubation of Neonates Born Extremely Preterm or With More Severe Respiratory Failure: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37399009. doi:10.1001/jamanetworkopen.2023.21644
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。